摘要
目的探讨哌拉西林钠他唑巴坦钠联合莫西沙星治疗重症肺炎的临床疗效及对患者血小板生成能力的影响。方法选取2018年3月至2020年3月本院收治的83例重症肺炎患者作为研究对象,根据用药方案不同分为常规组(n=40)和治疗组(n=43)。常规组采用哌拉西林钠他唑巴坦钠注射液,治疗组在常规组基础上联合莫西沙星治疗。比较两组临床疗效、炎症因子[白细胞介素-3(IL-3)、白细胞介素-11(IL-11)、促血小板生成素(TPO)]、血小板生成能力(血小板计数、CD61阳性网织血小板比)及不良反应发生情况。结果治疗组治疗总有效率为90.70%,高于常规组的72.50%,差异有统计学意义(P<0.05)。治疗后,两组IL-3、IL-11、TPO水平均低于治疗前,且治疗组低于常规组,差异有统计学意义(P<0.05)。治疗后,两组血小板计数、CD61阳性网织血小板比均低于治疗前,且治疗组均低于常规组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论哌拉西林钠他唑巴坦钠联合莫西沙星治疗重症肺炎疗效显著,可减少机体炎症因子释放及血栓发生风险,安全性较高,值得临床推广应用。
Objective To investigate the clinical efficacy of piperacillin sodium tazobactam sodium combined with moxifloxacin in the treatment of severe pneumonia and its the effect on platelet production.Methods 83 patients with severe pneumonia admitted to our hospital from March 2018 to March 2020 were selected as research subjects,and they were divided into conventional group(n=40)and treatment group(n=43)according to different medication regimens.The conventional group received piperacillin sodium tazobactam sodium injection,and the treatment group was combined with moxifloxacin on the basis of the conventional group.The clinical efficacy,inflammatory factors(interleukin-3[IL-3],interleukin-11[IL11],thrombopoietin[TPO]),thrombopoietic ability(platelet count,CD61-positive mesh platelet ratio)and adverse reaction ability of the two groups were compared.Results The total effective rate of the treatment group was 90.7%,higher than 72.50%of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of IL-3,IL-11 and TPO in the two groups were lower than before treatment,and the treatment group was lower than the conventional group,and the difference was statistically significant(P<0.05).After treatment,the platelet count and CD61-positive reticulated platelet ratio in the two groups were lower than before treatment,and the platelet count and CD61-positive reticulated platelet ratio in the treatment group were lower than those in the conventional group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Piperacillin sodium tazobactam sodium combined with moxifloxacin is effective in the treatment of severe pneumonia,which can reduce the release of inflammatory factors,reduce the risk of thrombosis,and has high safety,which is worthy of clinical application.
作者
王兵
孟凌
王婷婷
孙兵
WANG Bing;MENG Ling;WANG Tingting;SUN Bing(Department of Respiratory,Dengta City Central Hospital,Yaoyang,Liaoning,111300,China)
出处
《当代医学》
2022年第36期8-11,共4页
Contemporary Medicine
